Which statement about Staphylococcal enterotoxin B (SEB) vaccines or therapeutics is correct?

• A. There are FDA-licensed vaccines or therapeutics against SEB
• B. There are ongoing clinical trials for SEB vaccines but none approved
• C. SEB vaccines are widely available in civilian market
• D. There are no FDA-licensed vaccines or therapeutics against SEB

Answer: (D)

SEB acts as a potent superantigen from Staphylococcus aureus, and countermeasures are designed either to prevent toxin activity (vaccines) or to neutralize the toxin after exposure (therapeutics). Developing a safe and effective SEB vaccine or therapeutic is challenging because the toxin’s powerful immune-activating mechanism requires a robust, targeted immune response without provoking harmful reactions. Although researchers have pursued toxoid-based vaccines and toxin-neutralizing antibody approaches and some candidates have reached early human testing, none have completed the rigorous FDA licensure process. That means there are currently no FDA-licensed vaccines or therapeutics against SEB, and they are not available as approved products in the civilian market.